India CDSCO Drugs & Medical Devices
Material regulatory developments from Central Drugs Standard Control Organisation are tracked daily by Cresthaven Analytics. Over the last 90 days, 5 material briefs relevant to professionals operating in the healthcare & life sciences sector have been published below. Each brief is sourced directly from the primary regulatory feed, summarized for institutional readers, and scored for materiality.
Recent material activity
A selection of recent published briefs; this is not a complete archive.
CDSCO releases draft guidance for in-vitro diagnostic medical device manufacturers for public comment
India's Central Drugs Standard Control Organisation (CDSCO) published a draft guidance document on October 9, 2026, directed at manufacturers of in-vitro diagnostic (IVD) medical devices. The document is open for stakeho…
Read a full sample brief →CDSCO issues clarification on Export NOC requirements for previously approved recombinant DNA products
India's Central Drugs Standard Control Organisation (CDSCO) issued a public notice on October 12, 2026 clarifying whether domestic regulatory approval satisfies or modifies the Export No Objection Certificate requirement…
Read a full sample brief →CDSCO releases draft guidance for in-vitro diagnostic medical device manufacturers for stakeholder comment
India's Central Drugs Standard Control Organisation (CDSCO) published a draft guidance document on October 9, 2026 covering manufacturing standards for in-vitro diagnostic (IVD) medical devices. The release opens a stake…
Read a full sample brief →CDSCO issues circular on chronic kidney disease risks linked to unsupervised NSAID and antibiotic use
India's Central Drugs Standard Control Organisation (CDSCO) issued a circular on September 22, 2026 addressing indiscriminate use of non-steroidal anti-inflammatory drugs (NSAIDs) and antibiotics. The circular identifies…
Read a full sample brief →CDSCO issues public health alert against unauthorised cosmetics products circulating in the Indian market
India's Central Drugs Standard Control Organisation (CDSCO) issued a public health alert on September 14, 2026, identifying unauthorised cosmetics products as a consumer safety risk. The alert directs the public against …
Read a full sample brief →
Get every India CDSCO Drugs & Medical Devices brief delivered the day it lands
From $149/month
Cresthaven Analytics monitors Central Drugs Standard Control Organisation continuously, applying institutional materiality scoring to every release. Subscribers receive structured briefs via email, portal, and (Professional tier and above) real-time alerts.
View all tiers →